Phil is the GSK/Asthma Lung UK Chair of Respiratory Research and Consultant in Interstitial lung disease at the Royal Brompton Hospital, where he is the director of the NIHR Clinical Research Facility.
Phil qualified from Guy's, King's and St Thomas' School of Medicine in 2004, where he completed an intercalated BSc. in Molecular Genetics. He undertook his SHO training at Guy’s and St Thomas’ and upon completion of the MRCP attained an NIHR Academic Clinical Fellow position in Respiratory medicine at Imperial College. He spent the next two years training at St Mary’s Hospital and working with Professors Cookson, Moffatt and Johnston studying the respiratory microbiome in COPD.
An Asmarley training fellowship allowed him to undertake a PhD examining the host response to the respiratory microbiome in Idiopathic Pulmonary Fibrosis as part of the Prospective Study of Fibrosis In the Lung Endpoints (PROFILE) study with Professor Maher.
Having completed his clinical training in Respiratory and Critical Care Medicine he returned to Imperial joining the Fibrosis Research Group as a Senior Clinical Lecturer. He was awarded the Action for Pulmonary Fibrosis Mike Bray Fellowship which enabled him to establish his research group studying the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis.
et al., 2022, Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, The Lancet Respiratory Medicine, ISSN:2213-2600
et al., 2022, Residual lung abnormalities following COVID-19 hospitalization: interim analysis of the UKILD Post-COVID study, American Journal of Respiratory and Critical Care Medicine, ISSN:1073-449X
et al., 2022, Genome-wide enrichment of TERT rare variants in Idiopathic Pulmonary Fibrosis patients of Latino ancestry, American Journal of Respiratory and Critical Care Medicine, Vol:206, ISSN:1073-449X, Pages:903-905
et al., 2022, Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study, Respirology, ISSN:1323-7799
et al., 2022, Reply to: Functional criteria to define progressive pulmonary fibrosis: Searching for the Holy Grail., Am J Respir Crit Care Med